PEMBROLIZUMAB IN LUNG CANCER : LITERATURE REVIEW

R. Chacha, S. Afqir

Abstract


Lung cancer is the first cause of death cancer in the worldwide. There is an important development of agents which aimed
the PD-1/PD-L1 axis and that d has a great influence on the strategy of the treatment of lung cancer in first and second line.
Pembrolizumab is approved by the U.S. FDA for the treatment of advanced NSCLC progressed after other therapies and with expression of PD-L1.
This review highlights the results of recent clinical trials on pembrolizumab for the treatment of non-small cell lung cancer.


Keywords


immunotherapy, lung cancer, PD-1/PD-L1

Full Text:

PDF

References


Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet. 2011;378(9804):1727–1740

Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175–180.

Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer – is it becoming a reality? Nat Rev Clin Oncol. 2010;7(7):401–414.

Langer CJ. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol. 2015;38(4):422–430.

Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non–small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33(30):3488–3515.

Ettinger DS, Wood DE, Akerley W, et al. Non–Small cell lung cancer, version 6.2015. J Natl Compr Cancer Netw. 2015;13(5):515–524.

Shaw AT, Ou SI, Bang Y, et al. Crizotinib in ROS1-rearranged non–small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.

Tabrizi MA, Tseng C-M L, Roskos LK. Elimination Mechanisms of Therapeutic Monoclonal Antibodies. Drug Disc Today. 2006;11:81–88.

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461

Ahamadi M, Freshwater T, Prohn M, Li CH, de Alwis DP, de Greef R, Elassaiss- Schaap J, Kondic A, Stone JA. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors. CPT: pharmacometrics & systems pharmacology. 2016

Al-Moundhri M, O’Brien M, Souberbielle BE. Immunotherapy in lung cancer. Br J Cancer. 1998;78(3):282–288

Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028

Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Flotten O. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2016;27:1291-8

Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology. 2016;17:1497-508

Herbst RS PB, Jose Luis Perez-Gracia, Enriqueta Felip, Dong-Wan Kim, Ji-Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J. Fidler, Veerle Surmont, Gilberto Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled-Filhart, Ellie Im, Edward B. Garon. Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated advanced NSCLC.J Clin Oncol 34, 2016

Papadimitrakopoulou V, Patnaik A, Borghaei H, et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohorts A and C. J Clin Oncol. 2015;33(15_suppl):8031

Brahmer JR. Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024 (ID 7213). Abstract, as presented at the WCLC december 2016 in Vienna. 2016.

Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. Journal for mmunotherapy of cancer

Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2016.

Allison JP. Immune checkpoint blockade in cancer therapy: the 2015 Lasker-DeBakey clinical medical research award. JAMA. 2015;314(11):1113–1114

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.


Refbacks

  • There are currently no refbacks.